Emerging role of CCN family proteins in tumorigenesisand cancer metastasis (Review)

International Journal of Molecular Medicine

Volumn 36, Issue 6, 2015, Pages 1451-1463

  Li, Jun ^a,b   Ye, Lin ^b   Owen, Sioned ^b   Weeks, Hoi Ping ^b   Zhang, Zhongtao ^a   Jiang, Wen G ^b,c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cancers; CCN family proteins; Cell functions; Receptors; Signalling pathways

Indexed keywords

CCN PROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; CONNECTIVE TISSUE GROWTH FACTOR 2; CONNECTIVE TISSUE GROWTH FACTOR L; INTEGRIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; PROTEIN P44; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WNT 1 INDUCED SECRETED PROTEIN 1; WNT 1 INDUCED SECRETED PROTEIN 3; CTGF PROTEIN, HUMAN; CYR61 PROTEIN, HUMAN; CYSTEINE RICH PROTEIN 61; NOV PROTEIN, HUMAN; ONCOPROTEIN; REPRESSOR PROTEIN; WISP1 PROTEIN, HUMAN; WISP2 PROTEIN, HUMAN; WISP3 PROTEIN, HUMAN;

ADRENAL CORTEX TUMOR; ANGIOGENESIS; BLASTOCYST; BREAST CANCER; CANCER PROGNOSIS; CARCINOGENESIS; CELLULAR DISTRIBUTION; CHONDROSARCOMA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DISEASE COURSE; EMBRYO DEVELOPMENT; EMBRYOID BODY; ENCHONDROMA; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FIBROSIS; GALLBLADDER CANCER; GLIOMA; HUMAN; LIVER CANCER; LUNG CANCER; MELANOMA; METASTASIS; MOUTH CARCINOMA; NEPHROBLASTOMA; NEWBORN; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHABDOMYOSARCOMA; SALIVARY GLAND TUMOR; SIGNAL TRANSDUCTION; STOMACH CANCER; UTERINE CERVIX CANCER; WOUND HEALING; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

CARCINOGENESIS; CCN INTERCELLULAR SIGNALING PROTEINS; CONNECTIVE TISSUE GROWTH FACTOR; CYSTEINE-RICH PROTEIN 61; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS;

EID: 84945359845     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2390     Document Type: Review

References (141)

1. O'Brien TP, Yang GP, Sanders L, and Lau LF. Expression of cyr61, a growth factor-inducible immediate-early gene. Mol Cell Biol. 10: 3569-3577, 1990.
2. Bradham DM, Igarashi A, Potter RL, and Grotendorst GR. Connective tissue growth factor: A cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol. 114: 1285-1294, 1991.
3. Joliot V, Martinerie C, Dambrine G, Plassiart G, Brisac M, Crochet J, and Perbal B. Proviral rearrangements and overexpression of a new cellular gene (nov) in myeloblastosis-Associated virus type 1-induced nephroblastomas. Mol Cell Biol. 12: 10-21, 1992.
4. Pennica D, Swanson TA, Welsh JW, Roy MA, Lawrence DA, Lee J, Brush J, Taneyhill LA, Deuel B, Lew M, et al. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-Transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci USA. 95: 14717-14722, 1998.
5. Desnoyers L. Structural basis and therapeutic implication of the interaction of CCN proteins with glycoconjugates. Curr Pharm Des. 10: 3913-3928, 2004.
6. Zuo GW, Kohls CD, He BC, Chen L, Zhang W, Shi Q, Zhang BQ, Kang Q, Luo J, Luo X, et al. The CCN proteins: Important signaling mediators in stem cell differentiation and tumori-genesis. Histol Histopathol. 25: 795-806, 2010.
7. Holbourn KP, Acharya KR, and Perbal B. The CCN family of proteins: Structure-function relationships. Trends Biochem Sci. 33: 461-473, 2008.
8. Chen CC, and Lau LF. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol. 41: 771-783, 2009.
9. Hirschfeld M, zur Hausen A, Bettendorf H, Jäger M, and Stickeler E. Alternative splicing of Cyr61 is regulated by hypoxia and significantly changed in breast cancer. Cancer Res. 69: 2082 2090, 2009.
10. Ball DK, Surveyor GA, Diehl JR, Steffen CL, Uzumcu M, Mirando MA, and Brigstock DR. Characterization of 16- To 20-kilodalton (kDa) connective tissue growth factors (CTGFs) and demonstration of proteolytic activity for 38-kDa CTGF in pig uterine luminal flushings. Biol Reprod. 59: 828-835, 1998.
11. Sha W, and Leask A. CCN2 expression and localization in melanoma cells. J Cell Commun Signal. 5: 219-226, 2011.
12. Perbal B. CCN proteins: A centralized communication network. J Cell Commun Signal. 7: 169-177, 2013.
13. Joliot A, Triller A, Volovitch M, and Prochiantz A. Are embryonic forms of NCAM homeobox receptors? C R Acad Sci III (Suppl 9): 59-63, 1992 (In French).
14. Kyurkchiev S, Yeger H, Bleau AM, and Perbal B. Potential cellular conformations of the CCN3(NOV) protein. Cell Commun Signal. 2: 9, 2004.
15. Davies SR, Davies ML, Sanders A, Parr C, Torkington J, and Jiang WG. Differential expression of the CCN family member WISP-1, WISP-2 and WISP-3 in human colorectal cancer and the prognostic implications. Int J Oncol. 36: 1129-1136, 2010.
16. Wiesman KC, Wei L, Baughman C, Russo J, Gray MR, and Castellot JJ. CCN5, a secreted protein, localizes to the nucleus. J Cell Commun Signal. 4: 91-98, 2010.
17. Takada Y, Ye X, and Simon S. The integrins. Genome Biol. 8: 215, 2007.
18. Yang GP, and Lau LF. Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ. 2: 351-357, 1991.
19. Chen CC, Young JL, Monzon RI, Chen N, Todorovic V, and Lau LF. Cytotoxicity of TNFalpha is regulated by integrin mediated matrix signaling. EMBO J. 26: 1257-1267, 2007.
20. Holbourn KP, Perbal B, and Ravi Acharya K. Proteins on the catwalk: Modelling the structural domains of the CCN family of proteins. J Cell Commun Signal. 3: 25-41, 2009.
21. Segarini PR, Nesbitt JE, Li D, Hays LG, Yates JR III, and Carmichael DF. The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor is a receptor for connective tissue growth factor. J Biol Chem. 276: 40659-40667, 2001.
22. Gao R, and Brigstock DR. Low density lipoprotein receptor related protein (LRP) is a heparin-dependent adhesion receptor for connective tissue growth factor (CTGF) in rat activated hepatic stellate cells. Hepatol Res. 27: 214-220, 2003.
23. Mercurio S, Latinkic B, Itasaki N, Krumlauf R, and Smith JC. Connective-Tissue growth factor modulates WNT signalling and interacts with the WNT receptor complex. Development. 131: 2137-2147, 2004.
24. Nishida T, Kubota S, Fukunaga T, Kondo S, Yosimichi G, Nakanishi T, Takano-Yamamoto T, and Takigawa M. CTGF/Hcs24, hypertrophic chondrocyte-specific gene product, interacts with perlecan in regulating the proliferation and differ-entiation of chondrocytes. J Cell Physiol. 196: 265-275, 2003.
25. Abraham S, Riggs MJ, Nelson K, Lee V, and Rao RR. Characterization of human fibroblast-derived extracellular matrix components for human pluripotent stem cell propagation. Acta Biomater. 6: 4622-4633, 2010.
26. Yu H, and Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 92: 1472-1489, 2000.
27. Hwa V, Oh Y, and Rosenfeld RG. The insulin-like growth factor binding protein (IGFBP) superfamily. Endocr Rev. 20: 761-787, 1999.
28. Tomita N, Hattori T, Itoh S, Aoyama E, Yao M, Yamashiro T, and Takigawa M. Cartilage-specific over-expression of CCN family member 2/connective tissue growth factor (CCN2/CTGF) stim-ulates insulin-like growth factor expression and bone growth. PLoS One. 8: e59226, 2013.
29. Kleer CG, Zhang Y, Pan Q, and Merajver SD. WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer. Neoplasia. 6: 179-185, 2004.
30. Zhang Y, Pan Q, Zhong H, Merajver SD, and Kleer CG. Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells. Breast Cancer Res. 7: R1080-R1089, 2005.
31. Abreu JG, Ketpura NI, Reversade B, and De Robertis EM. Connective-Tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol. 4: 599-604, 2002.
32. Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H, Makino K, Ikeda E, Takata S, Kobayashi K, and Okada Y. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 16: 219-221, 2002.
33. Sakamoto K, Yamaguchi S, Ando R, Miyawaki A, Kabasawa Y, Takagi M, Li CL, Perbal B, and Katsube K. The nephro-blastoma overexpressed gene (NOV/ccn3) protein associates with Notch1 extracellular domain and inhibits myoblast differentiation via Notch signaling pathway. J Biol Chem. 277: 29399-29405, 2002.
34. Perbal B, Martinerie C, Sainson R, Werner M, He B, and Roizman B. The C-Terminal domain of the regulatory protein NOVH is sufficient to promote interaction with fibulin 1C: A clue for a role of NOVH in cell-Adhesion signaling. Proc Natl Acad Sci USA. 96: 869-874, 1999.
35. Li CL, Martinez V, He B, Lombet A, and Perbal B. A role for CCN3 (NOV) in calcium signalling. Mol Pathol. 55: 250-261, 2002.
36. Perbal B. NOV (nephroblastoma overexpressed) and the CCN family of genes: Structural and functional issues. Mol Pathol. 54: 57-79, 2001.
37. Moritani NH, Kubota S, Sugahara T, and Takigawa M. Comparable response of ccn1 with ccn2 genes upon arthritis: An in vitro evaluation with a human chondrocytic cell line stimulated by a set of cytokines. Cell Commun Signal. 3: 6, 2005.
38. Kok SH, Hou KL, Hong CY, Wang JS, Liang PC, Chang CC, Hsiao M, Yang H, Lai EH, and Lin SK. Simvastatin inhibits cytokine-stimulated Cyr61 expression in osteoblastic cells: A therapeutic benefit for arthritis. Arthritis Rheum. 63: 1010-1020, 2011.
39. Nozawa K, Fujishiro M, Kawasaki M, Kaneko H, Iwabuchi K, Yanagida M, Suzuki F, Miyazawa K, Takasaki Y, Ogawa H, et al. Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis. Arthritis Res Ther. 11: R174, 2009.
40. Kular L, Pakradouni J, Kitabgi P, Laurent M, and Martinerie C. The CCN family: A new class of inflammation modulators? Biochimie. 93: 377-388, 2011.
41. Parisi MS, Gazzerro E, Rydziel S, and Canalis E. Expression and regulation of CCN genes in murine osteoblasts. Bone. 38: 671-677, 2006.
42. Luo X, Ding L, and Chegini N. CCNs, fibulin-1C and S100A4 expression in leiomyoma and myometrium: Inverse association with TGF-beta and regulation by TGF-beta in leiomyoma and myometrial smooth muscle cells. Mol Hum Reprod. 12: 245-256, 2006.
43. Mason RM. Connective tissue growth factor(CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? J Cell Commun Signal. 3: 95-104, 2009.
44. Si W, Kang Q, Luu HH, Park JK, Luo Q, Song WX, Jiang W, Luo X, Li X, Yin H, et al. CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A induced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol. 26: 2955-2964, 2006.
45. Latinkic BV, Mercurio S, Bennett B, Hirst EM, Xu Q, Lau LF, Mohun TJ, and Smith JC. Xenopus Cyr61 regulates gastrulation movements and modulates Wnt signalling. Development. 130: 2429-2441, 2003.
46. Deng YZ, Chen PP, Wang Y, Yin D, Koeffler HP, Li B, Tong XJ, and Xie D. Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorige-nicity through beta-catenin-T-cell factor/Lef signaling. J Biol Chem. 282: 36571-36581, 2007.
47. Smerdel-Ramoya A, Zanotti S, Deregowski V, and Canalis E. Connective tissue growth factor enhances osteoblastogenesis in vitro. J Biol Chem. 283: 22690-22699, 2008.
48. Rydziel S, Stadmeyer L, Zanotti S, Durant D, Smerdel-Ramoya A, and Canalis E. Nephroblastoma overexpressed (Nov) inhibits osteoblastogenesis and causes osteopenia. J Biol Chem. 282: 19762-19772, 2007.
49. Yosimichi G, Nakanishi T, Nishida T, Hattori T, Takano Yamamoto T, and Takigawa M. CTGF/Hcs24 induces chondrocyte differentiation through a p38 mitogen-Activated protein kinase (p38MAPK), and proliferation through a p44/42 MAPK/extracellular-signal regulated kinase (ERK). Eur J Biochem. 268: 6058-6065, 2001.
50. Chen N, Chen CC, and Lau LF. Adhesion of human skin fibro-blasts to Cyr61 is mediated through integrin alpha 6beta 1 and cell surface heparan sulfate proteoglycans. J Biol Chem. 275: 24953-24961, 2000.
51. Grzeszkiewicz TM, Lindner V, Chen N, Lam SC, and Lau LF. The angiogenic factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin alpha(6)beta(1) and cell surface heparan sulfate proteoglycans. Endocrinology. 143: 1441-1450, 2002.
52. Leu SJ, Lam SC, and Lau LF. Pro-Angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. J Biol Chem. 277: 46248-46255, 2002.
53. Babic AM, Chen CC, and Lau LF. Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol. 19: 2958-2966, 1999.
54. Fukunaga-Kalabis M, Martinez G, Liu ZJ, Kalabis J, Mrass P, Weninger W, Firth SM, Planque N, Perbal B, and Herlyn M. CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. J Cell Biol. 175: 563-569, 2006.
55. Lin CG, Leu SJ, Chen N, Tebeau CM, Lin SX, Yeung CY, and Lau LF. CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J Biol Chem. 278: 24200-24208, 2003.
56. Liu H, Dong W, Lin Z, Lu J, Wan H, Zhou Z, and Liu Z. CCN4 regulates vascular smooth muscle cell migration and prolif-eration. Mol Cells. 36: 112-118, 2013.
57. Jian YC, Wang JJ, Dong S, Hu JW, Hu LJ, Yang GM, Zheng YX, and Xiong WJ. Wnt-induced secreted protein 1/CCN4 in liver fibrosis both in vitro and in vivo. Clin Lab. 60: 29-35, 2014.
58. Chowdhury S, Wang X, Srikant CB, Li Q, Fu M, Gong YJ, Ning G, and Liu JL. IGF-I stimulates CCN5/WISP2 gene expression in pancreatic β-cells, which promotes cell prolif-eration and survival against streptozotocin. Endocrinology. 155: 1629-1642, 2014.
59. Lake AC, and Castellot JJ Jr. CCN5 modulates the antiprolif-erative effect of heparin and regulates cell motility in vascular smooth muscle cells. Cell Commun Signal. 1: 5, 2003.
60. Kleer CG, Zhang Y, and Merajver SD. CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer. Cells Tissues Organs. 185: 95-99, 2007.
61. O'Brien TP, and Lau LF. Expression of the growth factor-inducible immediate early gene cyr61 correlates with chondrogenesis during mouse embryonic development. Cell Growth Differ. 3: 645-654, 1992.
62. Mo FE, Muntean AG, Chen CC, Stolz DB, Watkins SC, and Lau LF. CYR61 (CCN1) is essential for placental development and vascular integrity. Mol Cell Biol. 22: 8709-8720, 2002.
63. Baguma-Nibasheka M, and Kablar B. Pulmonary hypoplasia in the connective tissue growth factor (Ctgf) null mouse. Dev Dyn. 237: 485-493, 2008.
64. Chiou MJ, Chao TT, Wu JL, Kuo CM, and Chen JY. The physiological role of CTGF/CCN2 in zebrafish notochond devel-opment and biological analysis of the proximal promoter region. Biochem Biophys Res Commun. 349: 750-758, 2006.
65. Heath E, Tahri D, Andermarcher E, Schofield P, Fleming S, and Boulter CA. Abnormal skeletal and cardiac development, cardio-myopathy, muscle atrophy and cataracts in mice with a targeted disruption of the Nov (Ccn3) gene. BMC Dev Biol. 8: 18, 2008.
66. French DM, Kaul RJ, D'Souza AL, Crowley CW, Bao M, Frantz GD, Filvaroff EH, and Desnoyers L. WISP-1 is an osteo-blastic regulator expressed during skeletal development and fracture repair. Am J Pathol. 165: 855-867, 2004.
67. Jones JA, Gray MR, Oliveira BE, Koch M, and Castellot JJ Jr. CCN5 expression in mammals: I. Embryonic and fetal tissues of mouse and human. J Cell Commun Signal. 1: 127-143, 2007.
68. Hurvitz JR, Suwairi WM, Van Hul W, El-Shanti H, Superti-Furga A, Roudier J, Holderbaum D, Pauli RM, Herd JK, Van Hul EV, et al. Mutations in the CCN gene family member WISP3 cause progressive pseudorheumatoid dysplasia. Nat Genet. 23: 94-98, 1999.
69. Kutz WE, Gong Y, and Warman ML. WISP3, the gene responsible for the human skeletal disease progressive pseudorheumatoid dysplasia, is not essential for skeletal function in mice. Mol Cell Biol. 25: 414-421, 2005.
70. Hilfiker-Kleiner D, Kaminski K, Kaminska A, Fuchs M, Klein G, Podewski E, Grote K, Kiian I, Wollert KC, Hilfiker A, et al. Regulation of proangiogenic factor CCN1 in cardiac muscle: Impact of ischemia, pressure overload, and neurohumoral acti-vation. Circulation. 109: 2227-2233, 2004.
71. Lau LF, and Lam SC. The CCN family of angiogenic regulators: The integrin connection. Exp Cell Res. 248: 44-57, 1999.
72. Grotendorst GR. Connective tissue growth factor: A mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 8: 171-179, 1997.
73. Ujike K, Shinji T, Hirasaki S, Shiraha H, Nakamura M, Tsuji T, and Koide N. Kinetics of expression of connective tissue growth factor gene during liver regeneration after partial hepatectomy and D-galactosamine-induced liver injury in rats. Biochem Biophys Res Commun. 277: 448-454, 2000.
74. Hadjiargyrou M, Ahrens W, and Rubin CT. Temporal expression of the chondrogenic and angiogenic growth factor CYR61 during fracture repair. J Bone Miner Res. 15: 1014-1023, 2000.
75. Xu S-W, Leask A, and Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev. 19: 133-144, 2008.
76. Takehara K. Hypothesis: Pathogenesis of systemic sclerosis. J Rheumatol. 30: 755-759, 2003.
77. Leask A. Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal. 20: 1409-1414, 2008.
78. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, Takigawa M, Nakanishi T, and Takehara K. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. J Cell Physiol. 181: 153-159, 1999.
79. Lipson KE, Wong C, Teng Y, and Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair 5 (Suppl 1): S24, 2012.
80. Zhang L, Li Y, Liang C, and Yang W. CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis. Int J Mol Med. 33: 478-486, 2014.
81. Wiedmaier N, Müller S, Köberle M, Manncke B, Krejci J, Autenrieth IB, and Bohn E. Bacteria induce CTGF and CYR61 expression in epithelial cells in a lysophosphatidic acid receptor dependent manner. Int J Med Microbiol. 298: 231-243, 2008.
82. Kim SM, Park JH, Chung SK, Kim JY, Hwang HY, Chung KC, Jo I, Park SI, and Nam JH. Coxsackievirus B3 infection induces cyr61 activation via JNK to mediate cell death. J Virol. 78: 13479 13488, 2004.
83. Muehlich S, Schneider N, Hinkmann F, Garlichs CD, and Goppelt-Struebe M. Induction of connective tissue growth factor (CTGF) in human endothelial cells by lysophosphatidic acid, sphingosine-1-phosphate, and platelets. Atherosclerosis. 175: 261-268, 2004.
84. Sakamoto S, Yokoyama M, Zhang X, Prakash K, Nagao K, Hatanaka T, Getzenberg RH, and Kakehi Y. Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophos-phatidic acid. Endocrinology. 145: 2929-2940, 2004.
85. Gery S, Xie D, Yin D, Gabra H, Miller C, Wang H, Scott D, Yi WS, Popoviciu ML, Said JW, et al. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res. 11: 7243-7254, 2005.
86. Lv H, Fan E, Sun S, Ma X, Zhang X, Han DM, and Cong YS. Cyr61 is up-regulated in prostate cancer and associated with the p53 gene status. J Cell Biochem. 106: 738-744, 2009.
87. Schmitz P, Gerber U, Jüngel E, Schütze N, Blaheta R, and Bendas G. Cyr61/CCN1 affects the integrin-mediated migration of prostate cancer cells (PC-3) in vitro. Int J Clin Pharmacol Ther. 51: 47-50, 2013.
88. Goodwin CR, Lal B, Zhou X, Ho S, Xia S, Taeger A, Murray J, and Laterra J. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation. Cancer Res. 70: 2932-2941, 2010.
89. Xie D, Yin D, Tong X, O'Kelly J, Mori A, Miller C, Black K, Gui D, Said JW, and Koeffler HP. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res. 64: 1987-1996, 2004.
90. Harris LG, Pannell LK, Singh S, Samant RS, and Shevde LA. Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61. Oncogene. 31: 3370-3380, 2012.
91. Tsai MS, Hornby AE, Lakins J, and Lupu R. Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res. 60: 5603-5607, 2000.
92. Watari H, Xiong Y, Hassan MK, and Sakuragi N. Cyr61, a member of ccn (connective tissue growth factor/cysteine rich 61/nephro-blastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype. Gynecol Oncol. 112: 229-234, 2009.
93. Monnier Y, Farmer P, Bieler G, Imaizumi N, Sengstag T, Alghisi GC, Stehle JC, Ciarloni L, Andrejevic-Blant S, Moeckli R, et al. CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preir-radiated stroma. Cancer Res. 68: 7323-7331, 2008.
94. Chen PP, Li WJ, Wang Y, Zhao S, Li DY, Feng LY, Shi XL, Koeffler HP, Tong XJ, and Xie D. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One. 2: e534, 2007.
95. Chien W, Kumagai T, Miller CW, Desmond JC, Frank JM, Said JW, and Koeffler HP. Cyr61 suppresses growth of human endometrial cancer cells. J Biol Chem. 279: 53087-53096, 2004.
96. Brigstock DR. The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr Rev. 20: 189-206, 1999.
97. Maeta N, Osaki M, Shomori K, Inaba A, Kidani K, Ikeguchi M, and Ito H. CYR61 downregulation correlates with tumor progression by promoting MMP-7 expression in human gastric carcinoma. Oncology. 73: 118-126, 2007.
98. Croci S, Landuzzi L, Nicoletti G, Palladini A, Antognoli A, De Giovanni C, Nanni P, and Lollini PL. Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdo-myosarcomagenesis. Pathol Oncol Res. 13: 336-339, 2007.
99. Chien W, O'Kelly J, Lu D, Leiter A, Sohn J, Yin D, Karlan B, Vadgama J, Lyons KM, and Koeffler HP. Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. Int J Oncol. 38: 1741-1747, 2011.
100. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, and Mansel RE. Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer. 11: 781-791, 2004.
101. Jacobson A, and Cunningham JL. Connective tissue growth factor in tumor pathogenesis. Fibrogenesis Tissue Repair 5 (Suppl 1): S8, 2012.
102. Lin BR, Chang CC, Chen RJ, Jeng YM, Liang JT, Lee PH, Chang KJ, and Kuo ML. Connective tissue growth factor acts as a therapeutic agent and predictor for peritoneal carcinomatosis of colorectal cancer. Clin Cancer Res. 17: 3077-3088, 2011.
103. Bennewith KL, Huang X, Ham CM, Graves EE, Erler JT, Kambham N, Feazell J, Yang GP, Koong A, and Giaccia AJ. The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res. 69: 775-784, 2009.
104. Shakunaga T, Ozaki T, Ohara N, Asaumi K, Doi T, Nishida K, Kawai A, Nakanishi T, Takigawa M, and Inoue H. Expression of connective tissue growth factor in cartilaginous tumors. Cancer. 89: 1466-1473, 2000.
105. Chien W, Yin D, Gui D, Mori A, Frank JM, Said J, Kusuanco D, Marchevsky A, McKenna R, and Koeffler HP. Suppression of cell proliferation and signaling transduction by connective tissue growth factor in non-small cell lung cancer cells. Mol Cancer Res. 4: 591-598, 2006.
106. Kikuchi R, Tsuda H, Kanai Y, Kasamatsu T, Sengoku K, Hirohashi S, Inazawa J, and Imoto I. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res. 67: 7095-7105, 2007.
107. Li MH, Sanchez T, Pappalardo A, Lynch KR, Hla T, and Ferrer F. Induction of antiproliferative connective tissue growth factor expression in Wilms' tumor cells by sphingosine 1-phosphate receptor 2. Mol Cancer Res. 6: 1649-1656, 2008.
108. Gardini A, Corti B, Fiorentino M, Altimari A, Ercolani G, Grazi GL, Pinna AD, Grigioni WF, and D'Errico Grigioni A. Expression of connective tissue growth factor is a prognostic marker for patients with intrahepatic cholangiocarcinoma. Dig Liver Dis. 37: 269-274, 2005.
109. Lin BR, Chang CC, Che TF, Chen ST, Chen RJ, Yang CY, Jeng YM, Liang JT, Lee PH, Chang KJ, et al. Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer. Gastroenterology. 128: 9-23, 2005.
110. Maillard M, Cadot B, Ball RY, Sethia K, Edwards DR, Perbal B, and Tatoud R. Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues. Mol Pathol. 54: 275-280, 2001.
111. Manara MC, Perbal B, Benini S, Strammiello R, Cerisano V, Perdichizzi S, Serra M, Astolfi A, Bertoni F, Alami J, et al. The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol. 160: 849-859, 2002.
112. Glukhova L, Angevin E, Lavialle C, Cadot B, Terrier Lacombe MJ, Perbal B, Bernheim A, and Goguel AF. Patterns of specific genomic alterations associated with poor prognosis in high-grade renal cell carcinomas. Cancer Genet Cytogenet. 130: 105-110, 2001.
113. Perbal B. CCN3: Doctor Jekyll and Mister Hyde. J Cell Commun Signal. 2: 3-7, 2008.
114. Zhang T, Zhao C, Luo L, Xiang J, Sun Q, Cheng J, and Chen D. The clinical and prognostic significance of CCN3 expression in patients with cervical cancer. Adv Clin Exp Med. 22: 839-845, 2013.
115. Gupta N, Wang H, McLeod TL, Naus CC, Kyurkchiev S, Advani S, Yu J, Perbal B, and Weichselbaum RR. Inhibition of glioma cell growth and tumorigenic potential by CCN3 (NOV). Mol Pathol. 54: 293-299, 2001.
116. Bleau AM, Planque N, Lazar N, Zambelli D, Ori A, Quan T, Fisher G, Scotlandi K, and Perbal B. Antiproliferative activity of CCN3: Involvement of the C-Terminal module and post-Translational regulation. J Cell Biochem. 101: 1475-1491, 2007.
117. McCallum L, Lu W, Price S, Lazar N, Perbal B, and Irvine AE. CCN3 suppresses mitogenic signalling and reinstates growth control mechanisms in chronic myeloid leukaemia. J Cell Commun Signal. 6: 27-35, 2012.
118. Thibout H, Martinerie C, Créminon C, Godeau F, Boudou P, Le Bouc Y, and Laurent M. Characterization of human NOV in biological fluids: An enzyme immunoassay for the quanti-fication of human NOV in sera from patients with diseases of the adrenal gland and of the nervous system. J Clin Endocrinol Metab. 88: 327-336, 2003.
119. Xin LW, Martinerie C, Zumkeller W, Westphal M, and Perbal B. Differential expression of novH and CTGF in human glioma cell lines. Clin Mol Pathol. 49: M91-M97, 1996.
120. Sin WC, Bechberger JF, Rushlow WJ, and Naus CC. Dose dependent differential upregulation of CCN1/Cyr61 and CCN3/NOV by the gap junction protein Connexin43 in glioma cells. J Cell Biochem. 103: 1772-1782, 2008.
121. Fukunaga-Kalabis M, Martinez G, Telson SM, Liu ZJ, Balint K, Juhasz I, Elder DE, Perbal B, and Herlyn M. Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene. 27: 2552-2560, 2008.
122. Chuang JY, Chang AC, Chiang IP, Tsai MH, and Tang CH. Apoptosis signal-regulating kinase 1 is involved in WISP 1 promoted cell motility in human oral squamous cell carcinoma cells. PLoS One. 8: e78022, 2013.
123. Hashimoto Y, Shindo-Okada N, Tani M, Takeuchi K, Toma H, and Yokota J. Identification of genes differentially expressed in association with metastatic potential of K-1735 murine melanoma by messenger RNA differential display. Cancer Res. 56: 5266-5271, 1996.
124. Hashimoto Y, Shindo-Okada N, Tani M, Nagamachi Y, Takeuchi K, Shiroishi T, Toma H, and Yokota J. Expression of the Elm1 gene, a novel gene of the CCN (connective tissue growth factor, Cyr61/Cef10, and neuroblastoma overexpressed gene) family, suppresses in vivo tumor growth and metastasis of K-1735 murine melanoma cells. J Exp Med. 187: 289-296, 1998.
125. Soon LL, Yie TA, Shvarts A, Levine AJ, Su F, and Tchou-Wong KM. Overexpression of WISP-1 down-regulated motility and invasion of lung cancer cells through inhibition of Rac activation. J Biol Chem. 278: 11465-11470, 2003.
126. Yu C, Le AT, Yeger H, Perbal B, and Alman BA. NOV (CCN3) regulation in the growth plate and CCN family member expression in cartilage neoplasia. J Pathol. 201: 609-615, 2003.
127. Davies SR, Watkins G, Mansel RE, and Jiang WG. Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer. Ann Surg Oncol. 14: 1909-1918, 2007.
128. Tomimaru Y, Koga H, Yano H, de la Monte S, Wands JR, and Kim M. Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma. Liver Int. 33: 1100 1112, 2013.
129. Colli LM, Saggioro F, Serafini LN, Camargo RC, Machado HR, Moreira AC, Antonini SR, and de Castro M. Components of the canonical and non-canonical Wnt pathways are not mis-expressed in pituitary tumors. PLoS One. 8: e62424, 2013.
130. Ji J, Jia S, Ji K, and Jiang WG. Wnt1 inducible signalling pathway protein-2 (WISP 2/CCN5): Roles and regulation in human cancers (Review). Oncol Rep. 31: 533-539, 2014.
131. Banerjee S, Dhar G, Haque I, Kambhampati S, Mehta S, Sengupta K, Tawfik O, Phillips TA, and Banerjee SK. CCN5/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells. Cancer Res. 68: 7606-7612, 2008.
132. Dhar K, Banerjee S, Dhar G, Sengupta K, and Banerjee SK. Insulin-like growth factor-1 (IGF-1) induces WISP-2/CCN5 via multiple molecular cross-Talks and is essential for mitogenic switch by IGF-1 axis in estrogen receptor-positive breast tumor cells. Cancer Res. 67: 1520-1526, 2007.
133. Banerjee SK, and Banerjee S. CCN5/WISP-2: A micromanager of breast cancer progression. J Cell Commun Signal. 6: 63-71, 2012.
134. Yang Z, Yang Z, Zou Q, Yuan Y, Li J, Li D, Liang L, Zeng G, and Chen S. A comparative study of clinicopathological signif-icance, FGFBP1, and WISP-2 expression between squamous cell/adenosquamous carcinomas and adenocarcinoma of the gallbladder. Int J Clin Oncol. 19: 325-335, 2014.
135. Dhar G, Mehta S, Banerjee S, Gardner A, McCarty BM, Mathur SC, Campbell DR, Kambhampati S, and Banerjee SK. Loss of WISP-2/CCN5 signaling in human pancreatic cancer: A potential mechanism for epithelial-mesenchymal-Transition. Cancer Lett. 254: 63-70, 2007.
136. Kouzu Y, Uzawa K, Kato M, Higo M, Nimura Y, Harada K, Numata T, Seki N, Sato M, and Tanzawa H. WISP-2 expression in human salivary gland tumors. Int J Mol Med. 17: 567-573, 2006.
137. Thorstensen L, Diep CB, Meling GI, Aagesen TH, Ahrens CH, Rognum TO, and Lothe RA. WNT1 inducible signaling pathway protein 3, WISP-3, a novel target gene in colorectal carcinomas with microsatellite instability. Gastroenterology. 121: 1275-1280, 2001.
138. Cervello M, Giannitrapani L, Labbozzetta M, Notarbartolo M, D'Alessandro N, Lampiasi N, Azzolina A, and Montalto G. Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. Ann NY Acad Sci. 1028: 432-439, 2004.
139. Fang F, Zhao WY, Li RK, Yang XM, Li J, Ao JP, Jiang SH, Kong FZ, Tu L, Zhuang C, et al. Silencing of WISP3 suppresses gastric cancer cell proliferation and metastasis and inhibits Wnt/ β-catenin signaling. Int J Clin Exp Pathol. 7: 6447-6461, 2014.
140. Huang W, Zhang Y, Varambally S, Chinnaiyan AM, Banerjee M, Merajver SD, and Kleer CG. Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. Am J Pathol. 172: 893-904, 2008.
141. van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, and Merajver SD. A novel putative low-Affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res. 5: 2511-2519, 1999.